Pemziviptadil (PB1046)

A long-acting VIP analogue to manage pulmonary arterial hypertension and improve cardiac function

We are currently conducting a Phase 2B trial in pulmonary arterial hypertension (PAH), as well as a long-term, open label extension study of pemziviptadil in PAH subjects following completion of the VIP study.

In January 2021, PhaseBio announced presentation of data from a Phase 1b/2a pilot study highlighting three patients who received pemziviptadil (PB1046). The data, which were presented virtually at the 15th Pulmonary Vascular Research Institute (PVRI) World Congress on January 27, 2021, continue to highlight the favorable safety and tolerability profile of pemziviptadil, as well as clinically-meaningful, long-term improvement of six-minute walk test (6MWT) distance for one patient after 18 months of treatment. Additionally, the data demonstrate stability in functional status with no clinically-meaningful deterioration for two patients at two and six months after treatment. All three patients completed the study with no drug-related serious adverse events associated with study drug discontinuation and pemziviptadil appeared to be well tolerated.

For additional information, please visit:

Raymond Benza, MD, professor of medicine at Temple University, College of Medicine and James Magovern chair of cardiovascular research at the Allegheny Health Network, shares the limitations of the current medicines we have to treat the PAH. He provides more information on PhaseBio’s clinical trial investigating pemziviptadil for the treatment of patients with PAH.

If you have a question on our clinical trials, please email clinicaltrials@phasebio.com.